Company

Evopoint Biosciences' Imipenem/Cilastatin/Funobactam Wins NMPA Marketing Approval – Class 1 Triple‑Combination Antibiotic for HABP and VABP
Evopoint BiosciencesProduct approvals

Evopoint Biosciences’ Imipenem/Cilastatin/Funobactam Wins NMPA Marketing Approval – Class 1 Triple‑Combination Antibiotic for HABP and VABP

Evopoint Biosciences (SHA: 688837) announced that its Class 1 innovative drug, Imipenem, Cilastatin and Funobactam for Injection (IMI/FUN), has been approved for marketing by China's National Medical Products Administration (NMPA).…

Eli Lilly's Foundayo (Orforglipron) Wins NMPA Approval – First Oral GLP‑1 Receptor Agonist for Adult Weight Management in China

Eli Lilly’s Foundayo (Orforglipron) Wins NMPA Approval – First Oral GLP‑1 Receptor Agonist for Adult Weight Management in China

Fuzhou Luyan Pharmacy Secures Exclusive Greater China Rights to French Synergia Brand in Strategic Partnership with Curae LAB

Fuzhou Luyan Pharmacy Secures Exclusive Greater China Rights to French Synergia Brand in Strategic Partnership with Curae LAB

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Insilico Medicine Receives $10 Million Milestone Payment for XL309 Clinical Progress
AIFinance

Insilico Medicine Receives $10 Million Milestone Payment for XL309 Clinical Progress

Ascendis Pharma's TransCon hGH sBLA for Adult GHD Accepted by FDA
Ascendis PharmaMarket approval filings

Ascendis Pharma’s TransCon hGH sBLA for Adult GHD Accepted by FDA

Alibaba Health Reports 10.2% Revenue Growth and 72.8% Profit Increase in 2024 H1 Financials
Alibaba HealthE-commerce

Alibaba Health Reports 10.2% Revenue Growth and 72.8% Profit Increase in 2024 H1 Financials

Novo Nordisk's Ozempic Receives Positive CHMP Opinion for Kidney Disease Indication
Novo NordiskNYSE: NVO

Novo Nordisk’s Ozempic Receives Positive CHMP Opinion for Kidney Disease Indication

Show More